CorMedix beats Q2 revenue estimates on DefenCath growth, raises FY adjusted EBITDA guidance

CorMedix

13/08/2026 12:42

Overview
US biopharma firm's Q2 revenue rose, beating analyst expectations
EPS for Q2 beat analyst expectations
Company maintained FY 2026 revenue guidance and raised adjusted EBITDA outlook

Outlook
CorMedix maintains full-year 2026 consolidated revenue guidance of $325 mln to $345 mln
Company raises full-year 2026 adjusted EBITDA guidance to $125 mln to $140 mln
CorMedix narrows 2026 cash OpEx guidance to $145 mln to $155 mln

Result Drivers
DEFENCATH SALES - Growth in DefenCath sales, especially from large outpatient dialysis customers and onboarding of a large dialysis organization, drove revenue
MELINTA PORTFOLIO - Revenue benefited from full-quarter contribution of the acquired Melinta portfolio
COMMERCIAL EXPANSION - New multi-year supply agreement with a large dialysis operator expanded contract footprint to all top 5 US dialysis providers

Company press release: ID:nGNXb7h9d8

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$101.93 mln
$95.62 mln (5 Analysts)
Q2 EPS
Beat
$0.29
$0.24 (5 Analysts)
Q2 Net Income
Beat
$25.99 mln
$23.72 mln (4 Analysts)
Q2 Basic EPS
 
$0.33
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for CorMedix Inc. is $15.00, about 111.3% above its August 12 closing price of $7.10
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 14 three months ago

Reuters Recommended Reads
Aug 11 - Legend Biotech Q2 revenue beats estimates on commercial expansion
Aug 12 - Omeros Q2 YARTEMLEA net revenue jumps 190%
Aug 11 - Cardinal Health forecasts full-year profit above estimates on specialty drug strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)